APM
AVDL

Avidity Partners Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Avidity Partners Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-457,951
Closed -$3.7M – 71
2020
Q2 		$3.7M Buy
457,951
+75,951
+20% +$670K 0.24% 54
2020
Q1 		$3.03M Buy
+382,000
New +$2.93M 0.42% 49

Other funds holding AVDL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Avidity Partners Management's AVDL Position: Q3 2020 in Review

Avidity Partners Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 457,951 shares — an estimated $3.7M sold.

Avidity Partners Management first reported a position in AVDL in Q1 2020 and held it in 2 quarters. The position peaked at $3.7M in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

  • Avidity Partners Management reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Avidity Partners Management sold 457,951 Avadel Pharmaceuticals shares in Q3 2020, an estimated $3.7M.
  • Avidity Partners Management first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Avidity Partners Management's Avadel Pharmaceuticals position peaked at $3.7M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.